The Ongoing Battle for Patient Health

Week in Review: The Ongoing Battle for Patient Health

02.07.14 | By

Every day there is a war to wage against the world’s most devastating diseases. It is a fight we must win to make the world a safer, healthier place for our patients, and this week we discussed some of the battles currently underway.

The National Institutes of Health (NIH) announced the launch of the Accelerating Medicines Partnership (AMP) initiative in conjunction with 10 biopharmaceutical companies and non-profit organizations. AMP aims to change the current model for developing new diagnostics and treatments, particularly focusing on Alzheimer’s, type 2 diabetes and autoimmune disorders, including rheumatoid arthritis and lupus. By bringing together the brightest minds in the scientific community, AMP will fight to increase the number of new treatments for patients while reducing development time and cost, which could yield major benefits for all patients. Many of our battles against disease, however, also require help from those outside the scientific community.

On Tuesday we recognized World Cancer Day and celebrated the tremendous strides that have been made in the global fight against cancer. There are more than 3,000 medicines and vaccines in development aimed to manage, and hopefully beat, various types of cancer, but this fight cannot be won alone. According to a new World Health Organization report, half of all cancers could be prevented if individuals acted on current medical knowledge and addressed lifestyle factors. Check out their report and learn how you can do you part in the fight against cancer.

Our own Stephanie Fischer hosted an incredibly successful #RarePOV Tweet Chat that trended nationally. More than 100 individuals and organizations joined the discussion, which centered around the resources and support available ahead of Rare Disease Day on February 28, 2014. An estimated 30 million Americans suffer from one of the nearly 7,000 diseases that affect fewer than 200,000 people and are classified as rare. The chat was a dynamic conversation and resulted in interesting feedback as well as an overwhelming sense of camaraderie in the fight against rare diseases. If you weren’t able to join, you can see the conversation here.

The fight continues against these diseases and many more. Check back in with the Catalyst each week learn about the progress we’re making as we tackle some of the most devastating diseases. You can also follow us on Facebook and Twitter to keep these conversations going.



Hide Comments

More On PhRMA — powered by PhRMApedia


Cost in Context